Study of MRI and CT-Guided Radiation for Abdominopelvic Sarcomas
This study is looking at a new way to give radiation treatment for abdominopelvic sarcomas (cancers in the belly or pelvis). It uses Magnetic Resonance Image (MRI) and Computed Tomography (CT) scans to guide Stereotactic Body Radiation Therapy (SBRT). This helps make sure the radiation goes to the tumor and not healthy organs. You might be able to join if you are 12 years or older, have a sarcoma in your belly or pelvis that can be removed by surgery, and are generally in good health. The main goal is to see how much radiation side effects (morbidity) people have after 2 years. The study is currently unclear about its status and plans to enroll 20 participants.
- Study design
- This is an interventional study with no specified phase, planning to enroll 20 participants. It is a single-arm study, meaning all participants receive the same intervention.
- What's involved
- You would receive radiation treatment daily for 5 consecutive days, excluding weekends and holidays. Within 12 weeks of finishing radiation, you would have surgery to remove the tumor.
- Compensation
- Not stated in the trial record.
- Follow-up
- You would be followed by the radiation oncology team for 5 years after completing radiation therapy.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study of Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy for Abdominopelvic Sarcomas (MARS Trial)
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Radiation morbidity at 2 yearsAt 2 years
Evaluate the 2 year rate of grade ≥2 radiation morbidity, according to Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0.